We are live on !
Find out more
Johnson & Johnson Portfolio holdings
AUM
$799M
Turnover
17.65%
1-Year Est. Return
253.51%
This Fund
S&P 500
This Quarter Est. Return
+24.35%
1 Year Est. Return
+253.51%
3 Year Est. Return
+280.64%
5 Year Est. Return
+320.83%
10 Year Est. Return
–
AUM
$799M
AUM Growth
+$146M
(+22%)
Cap. Flow
+$11.1M
Cap. Flow % of AUM
Cap. Flow %
1.38%
Top 10 Holdings %
Top 10 Hldgs %
98.41%
Holding
17
New
1
Increased
–
Reduced
–
Closed
2
Avg Time Held
3.6
years
Top 10 Avg Time Held
2.8
years
Top 20 Avg Time Held
3.6
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cerebras Systems
CBRS
|
+$12.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Rallybio
RLYB
|
+$1.37M |
| 2 |
Nano X Imaging
NNOX
|
+$190K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.52% |
| 2 | Technology | 1.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Protagonist Therapeutics
PTGX
$8.62B
| $300M | 37.59% |
2,449,183
| – | – |
2021 Q3
19 quarters
|
|
2
Nanobiotix
NBTX
$1.07B
| $212M | 26.55% |
5,623,816
| – | – |
2023 Q3
11 quarters
|
|
3
MeiraGTx Holdings
MGTX
$902M
| $89.7M | 11.23% |
6,641,064
| – | – |
2021 Q3
19 quarters
|
|
4
Rapport Therapeutics
RAPP
$1.35B
| $74.4M | 9.31% |
1,784,517
| – | – |
2024 Q2
8 quarters
|
|
5
Contineum Therapeutics
CTNM
$254M
| $32.4M | 4.06% |
1,979,173
| – | – |
2024 Q2
8 quarters
|
|
6
Legend Biotech
LEGN
$3.51B
| $23.5M | 2.95% |
814,586
| – | – |
2021 Q3
19 quarters
|
|
7
CVRx
CVRX
$34.4M
| $20.7M | 2.59% |
4,024,861
| – | – |
2021 Q3
19 quarters
|
|
8
Xencor
XNCR
$1.68B
| $12M | 1.51% |
748,062
| – | – |
2021 Q4
18 quarters
|
|
|
9
Cerebras Systems
CBRS
$29.5B
| $11.8M | 1.48% |
+53,586
| New | +$12.6M |
2026 Q2
0 quarters
|
|
10
Fate Therapeutics
FATE
$219M
| $9.12M | 1.14% |
3,379,064
| – | – |
2021 Q3
19 quarters
|
|
11
Procept Biorobotics
PRCT
$1.04B
| $8.08M | 1.01% |
357,939
| – | – |
2021 Q3
19 quarters
|
|
12
Neumora Therapeutics
NMRA
$91M
| $3.14M | 0.39% |
1,849,445
| – | – |
2023 Q3
11 quarters
|
|
13
Vor Biopharma
VOR
$1.06B
| $989K | 0.12% |
53,732
| – | – |
2021 Q3
19 quarters
|
|
14
Standard BioTools
LAB
$252M
| $257K | 0.03% |
311,967
| – | – |
2024 Q1
9 quarters
|
|
15
Adicet Bio
ACET
$42.1M
| $197K | 0.02% |
22,779
| – | – |
2021 Q3
19 quarters
|
|
|
16
Nano X Imaging
NNOX
$31.8M
| – | – |
-83,554
| Closed | -$190K | – |
|
|
17
Rallybio
RLYB
$87.3M
| – | – |
-152,901
| Closed | -$1.37M | – |
|
Similar funds
Johnson & Johnson's Q2 2026 Portfolio in Review
As of Q2 2026, Johnson & Johnson held 17 positions worth $799M, up 22% from $652M the previous quarter. Its ten largest holdings account for 98% of the portfolio.
Johnson & Johnson's Q2 2026 filing shows 1 new and 2 closed positions. Its largest new stake was Cerebras Systems: 53,586 shares worth $11.8M. The largest sale was Rallybio, an estimated $1.37M.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Technology.
- Johnson & Johnson's largest Q2 2026 buy was Cerebras Systems: 53,586 shares worth $11.8M.
- Johnson & Johnson fully exited Rallybio in Q2 2026, selling an estimated $1.37M.
- Johnson & Johnson's ten largest holdings make up 98% of its $799M portfolio in Q2 2026.
- Johnson & Johnson opened 1 new position and closed 2 in Q2 2026.
- Johnson & Johnson's portfolio value rose 22% quarter-over-quarter to $799M.
Based on Johnson & Johnson's 13F filing for Q2 2026, filed 6 Aug 2026.